Metabolism of arsenic in human liver: the role of membrane transporters
- 18 December 2009
- journal article
- review article
- Published by Springer Nature in Archives of Toxicology
- Vol. 84 (1) , 3-16
- https://doi.org/10.1007/s00204-009-0499-7
Abstract
Metabolism of inorganic arsenic (iAs) is one of the key factors determining the character of adverse effects associated with exposure to iAs. Results of previous studies indicate that liver plays a primary role in iAs metabolism. This paper reviews these results and presents new data that link the capacity of human hepatocytes to metabolize iAs to the expression of specific membrane transporters. Here, we examined relationship between the expression of potential arsenic transporters (AQP9, GLUT2, P-gp, MRP1, MRP2, and MRP3) and the production and cellular retention of iAs and its methylated metabolites in primary cultures of human hepatocytes exposed for 24 h to subtoxic concentrations of arsenite. Our results show that the retention of iAs and methylarsenic metabolites (MAs) by hepatocytes exposed to sub-micromolar concentrations of arsenite correlates negatively with MRP2 expression. A positive correlation was found between MRP2 expression and the production of dimethylarsenic metabolites (DMAs), specifically, the concentration of DMAs in culture media. After exposures to high micromolar concentrations of arsenite which almost completely inhibited MAs and DMAs production, a positive correlation was found between the expression of GLUT2 and cellular retention of iAs and MAs. MRP3, AQP9, or P-gp expression had no effect on the production or distribution of iAs, MAs, or DMAs, regardless of the exposure level. Hepatocytes from seven donors used in this study did not contain detectable amounts of MRP1 protein. These data suggest that MRP2 plays an important role in the efflux of DMAs, thus, regulating kinetics of the methylation reactions and accumulation of iAs and MAs by human hepatocytes. The membrane transport of iAs by high-capacity GLUT2 transporters is not a rate-limiting step for the metabolism of arsenite at low exposure level, but may play a key role in accumulation of iAs after acute exposures which inhibit iAs methylation.Keywords
This publication has 71 references indexed in Scilit:
- High arsenic metabolic efficiency in AS3MT 287Thr allele carriersPharmacogenetics and Genomics, 2008
- Metabolism of Low-Dose Inorganic Arsenic in a Central European Population: Influence of Sex and Genetic PolymorphismsEnvironmental Health Perspectives, 2007
- Molecular Mechanisms of the Diabetogenic Effects of Arsenic: Inhibition of Insulin Signaling by Arsenite and Methylarsonous AcidEnvironmental Health Perspectives, 2007
- Mammalian glucose permease GLUT1 facilitates transport of arsenic trioxide and methylarsonous acidBiochemical and Biophysical Research Communications, 2006
- Monomethylarsonous acid induces transformation of human bladder cellsToxicology and Applied Pharmacology, 2006
- shRNA Silencing of AS3MT Expression Minimizes Arsenic Methylation Capacity of HepG2 CellsChemical Research in Toxicology, 2006
- Drug uptake and pharmacological modulation of drug sensitivity in leukemia by AQP9Biochemical and Biophysical Research Communications, 2004
- Arsenic trioxide uptake by human and rat aquaglyceroporinsBiochemical and Biophysical Research Communications, 2004
- Chronic Arsenic-Exposed Human Prostate Epithelial Cells Exhibit Stable Arsenic Tolerance: Mechanistic Implications of Altered Cellular Glutathione and Glutathione S-transferaseToxicology and Applied Pharmacology, 2002
- The role of the methylation in the detoxication of arsenate in the rabbitChemico-Biological Interactions, 1985